# Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants

> **NCT06566092** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Iovance Biotherapeutics, Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Soft Tissue Sarcoma
- Primary Central Nervous System Carcinoma
- Melanoma
- Rhabdomyosarcoma
- Ewing Sarcoma

## Interventions

- **BIOLOGICAL:** LN-145/LN-144

## Key facts

- **NCT ID:** NCT06566092
- **Lead sponsor:** Iovance Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-28
- **Primary completion:** 2026-07
- **Final completion:** 2028-07
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06566092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06566092, "Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06566092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*